BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 16133538)

  • 1. Prospective evaluation of carboplatin AUC dosing in patients with a BMI>or=27 or cachexia.
    Herrington JD; Tran HT; Riggs MW
    Cancer Chemother Pharmacol; 2006 Jan; 57(2):241-7. PubMed ID: 16133538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
    Ekhart C; Rodenhuis S; Schellens JH; Beijnen JH; Huitema AD
    Cancer Chemother Pharmacol; 2009 Jun; 64(1):115-22. PubMed ID: 18989671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of carboplatin clearance calculated by patient characteristics or 24-hour creatinine clearance: a comparison of the performance of three formulae.
    Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
    Cancer Chemother Pharmacol; 1998; 42(4):307-12. PubMed ID: 9744776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Difference of carboplatin clearance estimated by the Cockroft-Gault, Jelliffe, Modified-Jelliffe, Wright or Chatelut formula.
    Nagao S; Fujiwara K; Imafuku N; Kagawa R; Kozuka Y; Oda T; Maehata K; Ishikawa H; Koike H; Aotani E; Kohno I
    Gynecol Oncol; 2005 Nov; 99(2):327-33. PubMed ID: 16005943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measured versus estimated glomerular filtration rate in the Calvert equation: influence on carboplatin dosing.
    Donahue A; McCune JS; Faucette S; Gillenwater HH; Kowalski RJ; Socinski MA; Lindley C
    Cancer Chemother Pharmacol; 2001 May; 47(5):373-9. PubMed ID: 11391850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin.
    Holweger K; Lipp HP; Beijnen JH; Bokemeyer C; Hartmann JT
    Cancer Chemother Pharmacol; 2011 Sep; 68(3):693-701. PubMed ID: 21136060
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flat dosing of carboplatin is justified in adult patients with normal renal function.
    Ekhart C; de Jonge ME; Huitema AD; Schellens JH; Rodenhuis S; Beijnen JH
    Clin Cancer Res; 2006 Nov; 12(21):6502-8. PubMed ID: 17085665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A universal formula based on cystatin C to perform individual dosing of carboplatin in normal weight, underweight, and obese patients.
    Schmitt A; Gladieff L; Lansiaux A; Bobin-Dubigeon C; Etienne-Grimaldi MC; Boisdron-Celle M; Serre-Debauvais F; Pinguet F; Floquet A; Billaud E; Le Guellec C; Penel N; Campone M; Largillier R; Capitain O; Fabbro M; Houede N; Medioni J; Bougnoux P; Lochon I; Chatelut E
    Clin Cancer Res; 2009 May; 15(10):3633-9. PubMed ID: 19401344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
    De Jonge ME; Mathôt RA; Van Dam SM; Beijnen JH; Rodenhuis S
    Cancer Chemother Pharmacol; 2002 Sep; 50(3):251-5. PubMed ID: 12203108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
    Huitema AD; Mathôt RA; Tibben MM; Schellens JH; Rodenhuis S; Beijnen JH
    Clin Pharmacol Ther; 2000 Jun; 67(6):621-30. PubMed ID: 10872644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level.
    Ando M; Minami H; Ando Y; Saka H; Sakai S; Yamamoto M; Sasaki Y; Shimokata K; Hasegawa Y
    Clin Cancer Res; 2000 Dec; 6(12):4733-8. PubMed ID: 11156227
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of predictive formulae for glomerular filtration rate for carboplatin dosing in gynecological malignancies.
    de Lemos ML; Hsieh T; Hamata L; Levin A; Swenerton K; Djurdjev O; Vu T; Hu F; Conklin J; Malfair Taylor SC
    Gynecol Oncol; 2006 Dec; 103(3):1063-9. PubMed ID: 16875719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Population pharmacokinetic and limited sampling models for carboplatin administered in high-dose combination regimens with peripheral blood stem cell support.
    Shen M; Schilder RJ; Obasaju C; Gallo JM
    Cancer Chemother Pharmacol; 2002 Sep; 50(3):243-50. PubMed ID: 12203107
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of carboplatin administered with lobradimil to pediatric patients with brain tumors.
    Warren K; Gervais A; Aikin A; Egorin M; Balis FM
    Cancer Chemother Pharmacol; 2004 Sep; 54(3):206-12. PubMed ID: 15156345
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of carboplatin dosing in patients with a glomerular filtration rate greater than 125 mL/min: To cap or not to cap? A retrospective analysis and review.
    Morrow A; Garland C; Yang F; De Luna M; Herrington JD
    J Oncol Pharm Pract; 2019 Oct; 25(7):1651-1657. PubMed ID: 30336729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Modified Diet in Renal Disease equation for calculation of carboplatin dose.
    Shord SS; Bressler LR; Radhakrishnan L; Chen N; Villano JL
    Ann Pharmacother; 2009 Feb; 43(2):235-41. PubMed ID: 19193580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carboplatin dose calculation in lung cancer patients with low serum creatinine concentrations using CKD-EPI and Cockcroft-Gault with different weight descriptors.
    Kaag D
    Lung Cancer; 2013 Jan; 79(1):54-8. PubMed ID: 23131495
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimation of glomerular filtration rate in cancer patients with abnormal body composition and relation with carboplatin toxicity.
    Bretagne M; Jouinot A; Durand JP; Huillard O; Boudou Rouquette P; Tlemsani C; Arrondeau J; Sarfati G; Goldwasser F; Alexandre J
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):45-53. PubMed ID: 28508095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of expected AUC of carboplatin (CBDCA) predicted by Chatelut's formula in comparison with Calvert's].
    Nakamura T; Onishi Y; Kono T; Maeda T; Wada T; Hatae M
    Gan To Kagaku Ryoho; 1997 Mar; 24(5):579-83. PubMed ID: 9087291
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboplatin dosing in obese women with ovarian cancer: a Gynecologic Oncology Group study.
    Wright JD; Tian C; Mutch DG; Herzog TJ; Nagao S; Fujiwara K; Powell MA
    Gynecol Oncol; 2008 Jun; 109(3):353-8. PubMed ID: 18407341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.